



Press release - invitation for press

CAR T Cell Therapy; updates on efficacy and targets in 2nd European Meeting organized by EHA and EBMT

The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the second European CAR T Cell Meeting together in Sitges (Barcelona), Spain, on January 30 - February 1, 2020.

The meeting will be chaired by Professor Hermann Einsele, Chair of the EHA Scientific Working Group on Immune Therapies for Hematologic Disorders and Professor Christian Chabannon, Chair of the EBMT Cellular Therapy & Immunobiology Working Party and EBMT Scientific Council Vice-Chair.

Over 800 delegates participated in the first meeting in February 2019; 600 attended in person in Paris, France and 200 followed the live-stream. This second meeting will build on the knowledge and experience shared at the first joint meeting and will see the return of several Key Opinion Leaders to give updates on the rapid developments in this exciting therapy. The program will include a comprehensive outlook on the current research efforts in Europe, the USA and China to increase CAR T cell therapies efficacy and targets.

Registration for media representatives to the 2nd European CAR T Cell Meeting is now open. Press registration is free of charge and includes access to the scientific program. The Media and Embargo policy is available here.

Press registration is open to any media outlet and /or its press representative with a maximum of 2 registrations per outlet. The following representatives are eligible for media credentials; journalists/reporters, freelance journalists, online media, broadcast media (TV, radio), editors, medical journals, newsletters, and medical blogs.

The following representatives are not eligible for media credentials: Companies or organizations producing publications, videos, and/or other electronic media intended for internal use, marketing, advertising, financial analysis, or PR purposes and financial analysts.

If you wish to register for the press program, please send an email to communication@ehaweb.org or communications@ebmt.org with:

- a copy of your press credentials,
- a letter of assignment from the media organization being represented,
- two bylined medical/health/science articles published within the last 6 months.

Your credentials will be checked and when approved, you will receive a confirmation. Sharing your material with EHA and EBMT after publication is much appreciated.

About EHA

The European Hematology Association (EHA) promotes excellence in patient care, research and education in hematology.

EHA envisions a cure for all blood disorders by connecting hematologists worldwide, supporting their career development, harmonizing hematology education and advocating the interests of hematology and hematologists in the European arena.

With more than 5,000 members from 100+countries, EHA is Europe's largest professional organization supporting both clinicians and scientists around the globe in their efforts to cure blood diseases.

For more information about our organization, activities and advocacy, please visit www.ehaweb.org or follow us on Facebook (EuropeanHematologyAssociation), LinkedIn (EHA), Instagram (EHA_Hematology) and Twitter (@EHA_hematology).

About EBMT

The European Society for Blood and Marrow Transplantation (EBMT) is a not-for-profit medical and scientific organisation established in 1974. It is dedicated to fighting life-threatening blood cancers and diseases and improving patients' lives. The EBMT Members - more than 4,500 physicians, nurses, scientists and other healthcare professionals - participate in a unique collaborative network of peers involved in haematopoietic stem cell transplantation (HSCT) and cellular therapy research.

The EBMT patient Registry was established in the early 1970's. It is the only data source of its kind in Europe. The data are submitted continuously by more than 550 centres, including from outside Europe. The Registry holds data on more than 650,000 HSCT procedures including details on disease, transplant type, donor type and stem cell source. It contains data on patients that have undergone HSCT and also on patients receiving immunosuppressive therapies or other cell therapies. The Registry also offers the possibility to enter donors' follow-up data, which is crucial to ensure maximum donor safety. The Registry underpins extensive European research that translates into changes in clinical practice and improvements in patient outcome and care.

For further information about the EBMT, please visit the website: www.ebmt.org and follow us on Twitter: @TheEBMT.

Contact

For more information on this meeting, please contact communication@ehaweb.org or communication@ebmt.org.

